METHOD OF TREATING CANCER ASSOCIATED WITH A RAS MUTATION Russian patent published in 2020 - IPC A61K31/496 A61P35/00 

FIELD: pharmaceutical industry.

SUBSTANCE: present group of inventions refers to a method of treating cancer characterized by expressing a mutation form of RAS protein. Method of treating cancer characterized by expression of mutant form of RAS protein, involving introduction of Plinabulin to a subject, wherein the mutant form of the RAS protein is a mutant form of the NRAS protein, a mutant form of the HRAS protein or a mutant form of the KRAS protein, which contains one or more amino acid substitutions G12C, G12R, G12D, G12V, G12F, G12L, G12N, G13C, G13R, G13S, G13A, G13V, G13P, S17G, P34S, A59E, A59G, A59T, Q61K, Q61L, Q61R, Q61H, K117N, A146P, A146T, A146V and D153V. A method for inhibiting cell proliferation with a RAS mutation, involving bringing said cell into contact with a Plinabulin, wherein the mutant form of the RAS protein is a mutant form of the NRAS protein, a mutant form of the HRAS protein or a mutant form of the KRAS protein, which contains one or more amino acid substitutions selected from the group G12C, G12R, G12D, G12V, G12F, G12L, G12N, G13C, G13R, G13S, G13A, G13V, G13P, S17G, P34S, A59E, A59G, A59T, Q61K, Q61L, Q61R, Q61H, K117N, A146P, A146T, A146V and D153V. A method for inducing apoptosis in a cell containing a RAS mutation, involving bringing said cell into contact with a Plinabulin, wherein the mutant form of the RAS protein is a mutant form of the NRAS protein, a mutant form of the HRAS protein or a mutant form of the KRAS protein, which contains one or more amino acid substitutions G12C, G12R, G12D, G12V, G12F, G12L, G12N, G13C, G13R, G13S, G13A, G13V, G13P, S17G, P34S, A59E, A59G, A59T, Q61K, Q61L, Q61R, Q61H, K117N, A146P, A146T, A146V and D153V. A method for inhibiting the progression of cancer characterized by expression of a mutant form of RAS protein in a subject, involving administering Plinabulin to a subject, wherein the mutant form of the RAS protein is a mutant form of the NRAS protein, a mutant form of the HRAS protein or a mutant form of the KRAS protein, which contains one or more amino acid substitutions selected from the group G12C, G12R, G12D, G12V, G12F, G12L, G12N, G13C, G13R, G13S, G13A, G13V, G13P, S17G, P34S, A59E, A59G, A59T, Q61K, Q61L, Q61R, Q61H, K117N, A146P, A146T, A146V and D153V.

EFFECT: disclosed methods are effective methods of treating cancer associated with a mutation of oncogenic RAS genes.

26 cl, 7 dwg, 2 tbl, 6 ex